Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Imunon (IMNN)
NASDAQ:IMNN
Holding IMNN?
Track your performance easily
Earnings Data
Report Date
Mar 27, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.36Last Year’s EPS
-$0.5Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 07, 2024
|% Change Since: -11.42%
|Next Earnings Date:Mar 27, 2025
Earnings Call Sentiment|Positive
The earnings call was generally positive, with notable achievements in clinical trials and strategic advancements overshadowing the financial challenges and increased R&D spending.Company Guidance
During Imunon's Third Quarter 2024 earnings call, significant guidance was provided, particularly highlighting the outcomes of the OVATION 2 study, a Phase II trial involving 112 patients with advanced ovarian cancer. The study demonstrated a remarkable 11.1-month improvement in median overall survival, with some patients showing an increase of 17 months in survival. The results led to plans for a Phase III trial, expected to enroll approximately 500 women and set to begin in the first quarter of 2025. The company also announced a cash runway into the third quarter of 2025, with research and development expenses for Q3 2024 at $3.3 million, compared to $2 million in the previous year. IMNN-001, the focal point of their oncology efforts, showed potential blockbuster market opportunity exceeding $1.6 billion annually. Imunon is also actively pursuing partnerships for its PlaCCin platform, with strategic hires made to support upcoming initiatives.Groundbreaking Phase II Study Results
IMNN's Phase II OVATION 2 study showed an unprecedented improvement in median overall survival by 11.1 months in advanced ovarian cancer patients, indicating a potential new standard in cancer research.
Strong Endorsement and Future Plans
The study's compelling results led to unanimous support from the Scientific Advisory Board to proceed to a Phase III trial, with a potential U.S. market opportunity exceeding $1.6 billion annually.
Promising Initial Trials and Partnerships
The IMNN-101 Phase I study for a COVID-19 booster using the PlaCCin platform is fully enrolled with data expected before year-end, and partnership discussions are underway.
Strategic Hires
Two key hires to enhance business operations and legal functions, preparing the company for its upcoming Phase III trial and potential partnerships.
---
IMNN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
IMNN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $0.94 | $0.82 | -12.77% |
| Aug 14, 2024 | $1.08 | $0.96 | -11.11% |
| May 13, 2024 | $1.38 | $1.48 | +7.25% |
| Mar 28, 2024 | $1.40 | $1.64 | +17.14% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Imunon (IMNN) report earnings?
Imunon (IMNN) is schdueled to report earning on Mar 27, 2025, TBA Not Confirmed.
What is Imunon (IMNN) earnings time?
Imunon (IMNN) earnings time is at Mar 27, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is IMNN EPS forecast?
IMNN EPS forecast for the fiscal quarter 2024 (Q4) is -$0.36.
---